US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Neuroscience and Healthcare ETF

33.05

-0.2150-0.65%

Volume:1K

Turnover:37.66K

Market Cap:6.61M

PE:- -

High:33.15

Open:33.15

Low:33.05

Close:33.27

52wk High:43.01

52wk Low:26.17

Shares:200.00K

Float Shares:200.00K

Volume Ratio:1.34

T/O Rate:0.57%

Dividend:0.32

Dividend Rate:0.96%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Alkermes data show measurable improvements in ADHD, says H.C. Wainwright

Scholar Rock Grants Inducement Equity Awards Covering 83,102 Shares to New Hires

Scholar Rock Reports New Employee Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS

Alkermes Price Target Maintained with a $62.00/Share by Needham

Alkermes Plc : Baird Raises Target Price to $61 from $58

THOMSON REUTERS

Alkermes Says ADHD Drug Candidate Showed Meaningful Improvements in Phase 1b Study; Shares Up Pre-Bell

MT Newswires Live

U.S. Stocks on the MOVE-Accenture, Arhaus, Alkermes

Alkermes jumps 8% to $46.99 after Phase I adult ADHD data

Alkermes Shares Rise 6.5% Premarket After Positive Results from Early-Stage Study of Adhd Drug

THOMSON REUTERS

Alkermes announces Phase 1b results of ALKS 7290 in ADHD

Alkermes Reports Positive Phase 1b Proof-of-Concept Data for ALKS 7290 in Adult ADHD

Alkermes -Alks 7290 Generally Well Tolerated at All Doses in Healthy Volunteers and Adults with Adhd

THOMSON REUTERS

Alkermes Announces Positive Phase 1B Results Demonstrating Clinical Proof-of-Concept for Alks 7290 in Adults with Attention-Deficit Hyperactivity Disorder (Adhd)

THOMSON REUTERS

Alkermes - Phase 2 Study of Alks 7290 in Adults with Adhd Enrolling, Data Expected in 2027

THOMSON REUTERS

US Research Roundup-eBay, Sunbelt Rentals, T-Mobile

Scholar Rock Holding Corporation : JP Morgan Raises Target Price to $70 from $63

THOMSON REUTERS

Alkermes Files Form 3 for Director Anne Clem Whitaker`

Dianthus Therapeutics Chief Accounting Officer Edward Carr Disposes of Shares for $2.01 Million

US Stocks-S&P 500, NASDAQ Advance, Turning the Page on a Tumultuous Week

U.S. Small Caps Close Lower; Xenon Pharmaceuticals Posts Biggest Loss

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/IBRN/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","market":"US","secType":"STK","nameCN":"iShares Neuroscience and Healthcare ETF","latestPrice":33.05,"timestamp":1790878154206,"preClose":33.265,"halted":0,"volume":1138,"delay":0,"changeRate":-0.006463249661806806,"floatShares":200000,"shares":200000,"eps":0,"marketStatus":"Trading","change":-0.215,"latestTime":"10-01 14:09:47 EDT","open":33.15,"high":33.15,"low":33.05,"amount":37658.864424,"amplitude":0.003006,"askPrice":33.14,"askSize":400,"bidPrice":32.9,"bidSize":400,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1790884800000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":33.265,"sharesOutstanding":150000,"nav":33.20084,"aum":6640168,"dividendRate":0.009643,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":33.45,"preClose":33.265,"latestTime":"16:10 EDT","volume":6,"amount":199.56,"timestamp":1790799005063,"change":0.185,"changeRate":0.005561,"amplitude":0},"volumeRatio":1.342371,"impliedVol":0.0726,"impliedVolPercentile":0.3147},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","floatShares":200000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.342371,"shares":200000,"dividePrice":0.3187,"high":33.15,"amplitude":0.003006,"preClose":33.265,"low":33.05,"week52Low":26.1718,"pbRate":"--","week52High":43.01,"institutionHeld":0,"latestPrice":33.05,"eps":0,"divideRate":0.009643,"volume":1138,"delay":0,"ttmEps":0,"open":33.15,"prevYearClose":32.3193,"prevWeekClose":33.3342,"prevMonthClose":33.265,"prevQuarterClose":33.265,"fiveDayClose":33.525,"twentyDayClose":39.4587,"sixtyDayClose":39.9088},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBRN\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"IBRN","amount":0.319807,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2024-12-17","symbol":"IBRN","amount":0.10114,"announcedDate":"2024-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2023-12-20","symbol":"IBRN","amount":0.006303,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"IBRN","amount":0.008241,"announcedDate":"2023-05-12","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBRN\",market:\"US\",,,undefined,":[{"executeDate":"2023-06-07","recordDate":"2023-06-08","paymentDate":"2023-06-13","value":0.008241,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.006303,"currency":"USD"},{"executeDate":"2024-12-17","recordDate":"2024-12-17","paymentDate":"2024-12-20","value":0.10114,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-19","value":0.319807,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBRN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBRN\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669167844","title":"Alkermes data show measurable improvements in ADHD, says H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2669167844","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669167844?lang=en_us&edition=fundamental","pubTime":"2026-09-22 00:40","pubTimestamp":1790008814,"startTime":"0","endTime":"0","summary":"H.C. Wainwright keeps a Neutral rating on Alkermes (ALKS) after the company reported the first clinical evidence of an orexin-2 receptor agonist pr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alkermes-data-show-measurable-improvements-in-adhd-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alkermes-data-show-measurable-improvements-in-adhd-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSCH","ALKS","IBRN","FBT","MEDX","ABVC","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669616216","title":"Scholar Rock Grants Inducement Equity Awards Covering 83,102 Shares to New Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2669616216","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669616216?lang=en_us&edition=fundamental","pubTime":"2026-09-22 00:27","pubTimestamp":1790008046,"startTime":"0","endTime":"0","summary":"Scholar Rock grants inducement equity awards covering 83,102 shares to new hiresScholar Rock granted inducement equity awards covering 83,102 shares to 10 newly hired employees under its 2022 Induceme","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nNDL5QkCsN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","THNR","BK4139","SRRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669164272","title":"Scholar Rock Reports New Employee Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669164272","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669164272?lang=en_us&edition=fundamental","pubTime":"2026-09-22 00:00","pubTimestamp":1790006400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nTUA74KV9J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IBRN","THNR","SRRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669916926","title":"Alkermes Price Target Maintained with a $62.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2669916926","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669916926?lang=en_us&edition=fundamental","pubTime":"2026-09-21 22:11","pubTimestamp":1789999860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALKS/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","BK4139","PSCH","FBT","IBRN","MEDX","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669166716","title":"Alkermes Plc : Baird Raises Target Price to $61 from $58","url":"https://stock-news.laohu8.com/highlight/detail?id=2669166716","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669166716?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:33","pubTimestamp":1789997614,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45D0EZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IBRN","MEDX","FBT","ALKS","PSCH","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669976165","title":"Alkermes Says ADHD Drug Candidate Showed Meaningful Improvements in Phase 1b Study; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2669976165","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669976165?lang=en_us&edition=fundamental","pubTime":"2026-09-21 20:43","pubTimestamp":1789994623,"startTime":"0","endTime":"0","summary":"Alkermes  said Monday its drug candidate ALKS 7290 showed clinically meaningful improvements from baseline on exploratory endpoints in a phase 1b study in patients with attention-deficit hyperactivity disorder or ADHD.The company said it measured improvements using the Adult ADHD Investigator Symptom Rating Scale and Clinical Global Impression-Severity Scale after 14 days of treatment.ALKS 7290 was generally well-tolerated at all doses tested in healthy volunteers and adults with ADHD, the company said. The study enrolled 50 adults with ADHD in a double-blind, placebo-controlled, parallel-group trial with two cohorts, it added.The company said it enrolled the first of an expected 312 participants in a phase-2 study this month. The trial will evaluate the safety and efficacy of once-daily and split doses of ALKS 7290 compared to placebo, with data expected next year.Shares of the company were up over 7% in Monday's premarket activity.Price: 46.50, Change: +3.11, Percent Change: +7.17","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IBRN","PSCH","ALKS","MEDX","FBT","PSIL","BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669099168","title":"U.S. Stocks on the MOVE-Accenture, Arhaus, Alkermes","url":"https://stock-news.laohu8.com/highlight/detail?id=2669099168","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669099168?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:52","pubTimestamp":1789991524,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Accenture, Arhaus, AlkermesSeptember 21 (Reuters)-Wall Street futures advanced on Monday, led by AI stocks, as a 2% slide in oil prices pulled Treasury yields lower on sig","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nL6N45D0I4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014898.SGD","LMI3.UK","HOOC","COIW","BK4598","LU0545562505.USD","COII","MSTX","HOOX","LU1861220207.SGD","SG9999017495.SGD","07711","BK4581","ROBN","SG9999014880.SGD","LU0661504455.SGD","LU1430594728.SGD","LU1506573853.SGD","LU1032466523.USD","SG9999004303.SGD","LU1003077747.HKD","BK4551","BULL","SG9999014906.USD","3LMI.UK","SMST","FINX","CRML","OWNB","BK4134","IE00BSNM7G36.USD","ACN","ALKS","IE00BJJMRX11.SGD","SGXZ31699556.SGD","BK4588","LU1585245621.USD","BK4023","BK4533","MSII","BK4600","MSTC","HOII","LU0265550359.USD","BK4539","BK4554","CONX","BK4596","LU0289739343.SGD","HOOG","IMST","HOYY","BK4213","IE000M9KFDE8.USD","LU1228905037.USD","LU0342679015.USD","BK4108","IAI","LU1366333091.USD","SG9999018857.SGD","LU1861217088.USD","LU1894683264.USD","GLND","MSTP","MSOO","HK0000819398.USD","MSTR","MSST","SMI3.UK","BULU","LU0868494617.USD","LU0942090050.USD","BK4112","MST","LU0545039389.USD","LU0323239441.USD","LU1989772840.SGD","BK4535","3SMI.UK","PSCH","LU0738911758.USD","BLCK","SG9999014914.USD","HOOW","BK4547","LU0323240290.USD","REXC","LU0149725797.USD","IE00BFSS7M15.SGD","MEDX","WNTR","COIO","CONY","LU1883839398.USD","LU1989772923.USD","07311","LU1116320901.HKD","LU2360107671.USD","MSTZ","SG9999018865.SGD","LU0477156953.USD","COIX","LU1116320737.USD","09799","LU2211815571.USD","LU2133065610.SGD","HOOD","MSTK","LU0130102774.USD","LU0175139822.USD","MSTY.UK","LU0511384066.AUD","BPAY","IE00BFSS8Q28.SGD","LU1235294995.USD","09399","FIAT","LU1861559042.SGD","LU2596442595.SGD","MSTW","IBLC","09311","COIG","SGXZ23171101.USD","BK4534","LU0949170772.SGD","BK4178","COIA","CRMX","LU0289961442.SGD","LU2381873111.SGD","CRMU","CONI","HOOY","LU0157215616.USD","DAPP","FBT","BITQ","LU1228905540.USD","IBRN","IE00BJJMRY28.SGD","PSIL","LU1894683348.USD","BK4127","BK4561","IE00B7KXQ091.USD","BK4585","LU1823568750.SGD","LU1861558580.USD","07399","CRPT","LU0265550946.USD","MSTU","LU0130517989.USD","MSTY","BK4125","BULG","BK4566","CUE","FDIG","07799","LU0648001328.SGD","MTYY","WBD","09711","APED","HODU","LU0868494708.USD","BK4516","HOOZ","LU0980610538.SGD","LU0289960550.SGD","COIN","MSDD","COYY","GRML","IE00BHPRN162.USD","LU0081259029.USD","IE0004445015.USD","BK4595","HOOI","LU1201861249.SGD","ARHS","ICOI","BKCH","LU1046421795.USD","BK4139","PSKY","BK4168","CONL","LU2247934214.USD","LU0553294199.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669163577","title":"Alkermes jumps 8% to $46.99 after Phase I adult ADHD data","url":"https://stock-news.laohu8.com/highlight/detail?id=2669163577","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669163577?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:50","pubTimestamp":1789991414,"startTime":"0","endTime":"0","summary":"07:46 EDT Alkermes (ALKS) jumps 8% to $46.99 after Phase I adult ADHD data Published first on TheFly – the ultimate source for real-time, market-mo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alkermes-jumps-8-to-46-99-after-phase-i-adult-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alkermes-jumps-8-to-46-99-after-phase-i-adult-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","PSCH","MEDX","ABVC","BK4139","IBRN","FBT","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669150485","title":"Alkermes Shares Rise 6.5% Premarket After Positive Results from Early-Stage Study of Adhd Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150485","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669150485?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:07","pubTimestamp":1789988867,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45A0RA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MEDX","PSIL","IBRN","FBT","BK4139","ALKS","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669916887","title":"Alkermes announces Phase 1b results of ALKS 7290 in ADHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2669916887","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669916887?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:05","pubTimestamp":1789988737,"startTime":"0","endTime":"0","summary":"Alkermes (ALKS) announced topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company’s novel, investigational orexin 2...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alkermes-announces-phase-1b-results-of-alks-7290-in-adhd-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alkermes-announces-phase-1b-results-of-alks-7290-in-adhd-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALKS","PSIL","IBRN","MEDX","BK4139","ABVC","PSCH","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669415062","title":"Alkermes Reports Positive Phase 1b Proof-of-Concept Data for ALKS 7290 in Adult ADHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2669415062","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669415062?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:01","pubTimestamp":1789988517,"startTime":"0","endTime":"0","summary":"Alkermes reports positive Phase 1b proof-of-concept data for ALKS 7290 in adult ADHDAlkermes reported positive Phase 1b topline results for ALKS 7290 in adults with ADHD; results have already been pre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nNDL2WW99h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALKS","PSIL","BK4139","PSCH","IBRN","FBT","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669505181","title":"Alkermes -Alks 7290 Generally Well Tolerated at All Doses in Healthy Volunteers and Adults with Adhd","url":"https://stock-news.laohu8.com/highlight/detail?id=2669505181","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669505181?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:00","pubTimestamp":1789988400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nTUA9RZ6JR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALKS","FBT","MEDX","BK4139","PSCH","PSIL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669150548","title":"Alkermes Announces Positive Phase 1B Results Demonstrating Clinical Proof-of-Concept for Alks 7290 in Adults with Attention-Deficit Hyperactivity Disorder (Adhd)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150548","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669150548?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:00","pubTimestamp":1789988400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nTUA9RZ6JR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSCH","MEDX","PSIL","ALKS","IBRN","BK4139","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669150512","title":"Alkermes - Phase 2 Study of Alks 7290 in Adults with Adhd Enrolling, Data Expected in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150512","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669150512?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:00","pubTimestamp":1789988400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nTUA9RZ6JR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBT","IBRN","ALKS","PSCH","MEDX","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669155576","title":"US Research Roundup-eBay, Sunbelt Rentals, T-Mobile","url":"https://stock-news.laohu8.com/highlight/detail?id=2669155576","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669155576?lang=en_us&edition=fundamental","pubTime":"2026-09-21 15:41","pubTimestamp":1789976490,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP-eBay, Sunbelt Rentals, T-MobileSept 21 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including eBay, Sunbelt Ren","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nL4N45D0ES:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CL","SPAM","THNR","MTZ","TMUS","OKTA","AIRR","BUG","AMZA","EWTX","LU0109394709.USD","IBRN","LU2322448957.HKD","PKB","TTMX","GOSS","MLPA","PAGP","SUNB","LU1064131342.USD","THO","CDW","BLSM","ONLN","IHAK","IQMX","OKTG","EMLP","PSWD","AMLP","MCHB","EBAY","SRRK","BK4504","FOUR","AMRZ","HUBS","ARHS","OKTX","BK4528","HAKY","LU0251131958.USD","NBIX","BKH","CLIX","LU2095319765.USD","LU1201861249.SGD","PAA","STBQ","TTMI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669132568","title":"Scholar Rock Holding Corporation : JP Morgan Raises Target Price to $70 from $63","url":"https://stock-news.laohu8.com/highlight/detail?id=2669132568","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669132568?lang=en_us&edition=fundamental","pubTime":"2026-09-21 12:29","pubTimestamp":1789964962,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45A0SJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","SRRK","BK4139","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668789973","title":"Alkermes Files Form 3 for Director Anne Clem Whitaker`","url":"https://stock-news.laohu8.com/highlight/detail?id=2668789973","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668789973?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:48","pubTimestamp":1789764537,"startTime":"0","endTime":"0","summary":"Alkermes files Form 3 for director Anne Clem Whitaker`Alkermes director Anne Clem Whitaker filed a Form 3 initial statement of beneficial ownership dated Sept. 14, 2026.Disclaimer:This news brief was ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nNDL7wyxYN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","IBRN","MEDX","PSCH","BK4139","ALKS","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668973172","title":"Dianthus Therapeutics Chief Accounting Officer Edward Carr Disposes of Shares for $2.01 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2668973172","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668973172?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:37","pubTimestamp":1789763825,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Chief Accounting Officer Edward Carr disposes of shares for $2.01 millionDianthus Therapeutics reported Chief Accounting Officer Edward Carr exercised stock options for 20,000 sh","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nNDL6j4XMn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Dianthus Therapeutics Chief Accounting Officer Edward Carr Disposes of Shares for $2.01 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH","IBRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668097355","title":"US Stocks-S&P 500, NASDAQ Advance, Turning the Page on a Tumultuous Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2668097355","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668097355?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:20","pubTimestamp":1789762837,"startTime":"0","endTime":"0","summary":"US STOCKS-S&P 500, Nasdaq advance, turning the page on a tumultuous weekNEW YORK, Sept 18 (Reuters)-Wall Street closed a volatile week on a muted note on Friday as benchmark US Treasury yields topped ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nL6N45A15E:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE","BK4139","SBIO","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668973504","title":"U.S. Small Caps Close Lower; Xenon Pharmaceuticals Posts Biggest Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2668973504","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668973504?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:20","pubTimestamp":1789762800,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of small-cap companies fell Friday, as the Russell 2000 Index declined 0.5%, and the S&P Small Cap 600 Index was down 0.5%.Among companies with a market value of $1 billion to $6.7 billion, Xenon Pharmaceuticals Inc. was the biggest laggard during the session, dropping 31%, followed by shares of Genius Sports Ltd., which dropped 13%. Shares of NuScale Power Corp. dropped 8.5%, SL Science Holding Ltd. shares tumbled 8.0%, and Rush Street Interactive Inc. plunged 7.7%.Securitize Corp. was the best performer, surging 22%, followed by Bitdeer Technologies Group, which jumped 15%. MARA Holdings Inc. shares jumped 14%, Sharplink Inc. surged 13%, and shares of Sigma Lithium Corp. surged 12%.Major U.S. stock indexes ended Friday mixed as the Nasdaq Composite Index added 0.4%. Meanwhile, the S&P 500 Index added 0.2%, and the Dow Jones Industrial Average fell 0.2%.Data source: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","XENE","BK4139","SBIO"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}